INT J TUBERC LUNG DIS 13(6):719–725
© 2009 The Union
Risk factors for failure to complete a course of latent
tuberculosis infection treatment in Salvador, Brazil
A. Machado Jr.,*† B. Finkmoore,‡ K. Emodi,‡ I. Takenami,* T. Barbosa,§ M. Tavares,* M. G. Reis,*¶
S. Arruda,*# L. W. Riley‡
* Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, † Hospital Especializado Octávio Mangabeira, Salvador,
Bahia, Brazil; ‡ School of Public Health, University of California, Berkeley, California, USA; § Laboratório Integrado de
Microbiologia e Imunorregulação, ¶ Laboratório de Patologia e Biologia Molecular, and # Laboratório Avançado de
Saúde Pública, Centro de Pesquisas Gonçalo Moniz, Salvador, Bahia, Brazil
SUMMARY
BACKGROUND:
Although treatment of latent tuberculosis infection (LTBI) is an essential component of tuberculosis (TB) control in countries such as the United
States, it is not widely practiced in most TB-endemic
countries.
O B J E C T I V E : To examine the practice of and adherence
to LTBI treatment in a high-risk population in Brazil.
D E S I G N : We followed household contacts (HHCs) of
patients hospitalized with pulmonary TB in Salvador,
Brazil, for 6 months after they initiated LTBI treatment
with isoniazid (INH). HHCs were asked to return to the
hospital once a month for 6 months for follow-up visits
and INH refills.
R E S U LT S : Of 101 HHCs who initiated LTBI treatment,
54 (53.5%) completed the 6-month regimen. The risk of
treatment non-completion was significantly higher in
HHCs who reported side effects to INH (RR 2.69,
95%CI 1.3–5.8, P = 0.01), and in those who had to
take two buses for a one-way trip to the hospital (RR
1.8, 95%CI 1.01–3.3, P = 0.04). Of the 101 HHCs, 29
(28.7%) did not return for any follow-up visits; these
HHCs were significantly more likely to have a 2-bus
commute to the hospital compared to HHCs who completed treatment (OR 20.69, 95%CI 2.1–208.4, P =
0.01).
C O N C L U S I O N : Nearly 50% of HHCs at high risk for
developing TB completed a 6-month course of LTBI
treatment. Completion of LTBI treatment was most affected by medication intolerance and commuting difficulties for follow-up visits.
K E Y W O R D S : latent tuberculosis infection; isoniazid;
adherence; household contacts
A HIGH PREVALENCE of latent tuberculosis infection (LTBI) occurs among close contacts of persons
with pulmonary tuberculosis (TB).1–3 Individuals infected with Mycobacterium tuberculosis are at an
increased risk of developing active disease during
the first years after new infection.4–6 Treatment of
LTBI is therefore a strategic component of TB control
programs.7,8
Isoniazid (INH) significantly reduces the risk of
progression from LTBI to active disease,6,9 and is a
mainstay of TB control in industrialized countries
such as the United States. In most TB-endemic countries, contact investigation is accorded low priority,
and formal LTBI treatment programs do not exist.1
TB prevention relies mostly on bacille CalmetteGuérin (BCG) vaccination in these countries. The
World Health Organization (WHO) currently recommends INH preventive treatment only for children
aged <5 years who are contacts of infectious cases.10,11
Despite the lack of specific recommendations for the
broader population, WHO guidelines state that programs that provide screening and INH treatment to
all household contacts (HHCs) of infectious cases—
both children and adults—are desirable.11 Reasons
often cited for lack of LTBI treatment of the general
population in developing countries include the lack
of standardized diagnostic criteria for LTBI, the inability to distinguish the effect of BCG vaccination
on tuberculin skin test (TST) results, the possibility of
mistakenly treating those who may have active disease with INH alone, and the side effects of INH. Information related to the feasibility, adherence, and acceptability of LTBI treatment is thus limited in most
TB-endemic countries.
The Brazilian National TB Control Program (NTP)
recommends a 6-month LTBI treatment course of
daily INH for children aged ⩽15 years who live in
the same household as a sputum-positive case, who
are not BCG-vaccinated, and who have a TST reaction ⩾10 mm, and for BCG-vaccinated children aged
Correspondence to: Almério Machado Jr, Laboratorio Avancado de Saúde Pública (LASP), rua Waldemar Palção 121, Candeal, Salvador 40296 710, Bahia, Brazil. Tel: (+55) 713 176 2232. Fax: (+55) 713 176 2327. e-mail: almeriojr@yahoo.com.br
Article submitted 19 November 2008. Final version accepted 18 January 2009.
720
The International Journal of Tuberculosis and Lung Disease
⩽15 years who have a TST reaction ⩾15 mm.12 The
Brazilian NTP guidelines also state that treatment for
all HHCs of pulmonary TB cases with a TST reaction ⩾10 mm should be considered.12 However, these
recommendations are not widely followed. In this
study, we studied HHCs with documented LTBI exposed to hospitalized TB index cases in Salvador, Brazil, to observe what happens to this high-risk cohort
in a TB-endemic setting when they are offered LTBI
treatment.
charts. Data were entered into a desktop computer
maintained at Gonçalo Moniz Research Center with
Epi Info Version 3.4.3 (Centers for Disease Prevention and Control, Atlanta, GA, USA, 2007).
Distance between the residence of the study participant and HEOM was calculated in km with Google
maps.∗ We determined the number of buses necessary for each study participant to commute one way
between their residence and the hospital by consulting the Salvador Transportation Agency.
METHODS
Laboratory test
TST was performed by a trained nursing staff with
0.1 ml of purified protein derivative (PPD) RT23
(2 tuberculin units [TU], Statens Serum Institute, Copenhagen, Denmark). The reaction was read 72 h
later by the chest physician on the study team (AM).
The cut-off point for a positive reaction was an induration diameter of ⩾10 mm, according to the Brazilian NTP guidelines.12
Setting
We prospectively enrolled study participants between
November 2006 and February 2008 from Hospital
Especializado Octávio Mangabeira (HEOM), a 217bed public chest disease hospital in Salvador, Brazil.
Salvador is the capital of Bahia state, with a population of 2 714 018 in 2006.13 In 2005, it had a TB incidence of 88 per 100 000 population—one of the
highest TB incidence rates in Brazil.14 Salvador does
not have an active TB contact investigation program.
Study participants
The study was approved by the respective human subjects committees of Oswaldo Cruz Foundation in Salvador, Brazil, and the University of California at Berkeley, USA. Informed consent was obtained from all
subjects who agreed to participate in the study.
Index cases
Index cases were defined as hospitalized patients with
symptoms consistent with TB and one or more of the
following characteristics: 1) chest radiography suggestive of TB; 2) sputum samples that contained acid-fast
bacilli on microscopy; 3) individuals who responded
to anti-tuberculosis drugs. Sputum was analyzed with
the Ziehl-Neelsen staining method and its burden was
classified as negative, 1+, 2+ or 3+, as previously reported.15 The characteristics of the index cases are
described elsewhere.16
Household contacts
Contacts who spent at least 100 h with the index case
during the latter’s symptomatic period and who lived
in the same residence were considered HHCs and
were invited to participate in the study.16,17
Data collection
HHCs who were enrolled underwent TST and were interviewed by members of the study team (AM, KE, IT)
when they returned for TST reading. A standardized
questionnaire was used to collect the interview data.
Study participants were asked about their current use
of medications and diabetes status. They were not directly asked about their human immunodeficiency virus (HIV) status, nor were the data sought from clinic
Treatment
Six months of daily INH treatment was offered to eligible HHCs with a positive TST result; this is the
standard LTBI treatment regimen in Brazil.12 INH
was supplied to the study participants by the Brazilian Ministry of Health without charge. INH treatment was not offered to patients with a positive TST
if they were pregnant or if they were diagnosed with
active TB.
Following consent, participants received a 1-month
supply of INH, 5 mg/kg of body weight (maximum
300 mg), and were asked to return every 30 days for
refills. HHCs who completed LTBI treatment were defined as those who returned to HEOM every 30 days
for 6 months and received six 30-day supplies of INH.
HHCs who did not complete treatment were defined
as those who missed at least one but not all of the
follow-up visits and missed an INH refill. HHCs who
were immediately lost to follow-up were defined as
those who did not return to HEOM for a follow-up
visit or any INH refills.
Participants were instructed to terminate therapy
immediately upon onset of any adverse reactions (nausea, vomiting, jaundice, abdominal pain, headache,
peripheral neuropathy, itching, rash). Blood tests to
monitor liver toxicity were conducted for patients with
major gastrointestinal symptoms. Payment or incentives were not offered.
Statistics
The database was created in Epi Info Version 3.4.3.
Interview data were entered into Epi Info by members
of the study team (KE, IT) and were analyzed using
Stata 10.0 Intercooled (StataCorp, College Station, TX,
USA). Patients who completed the 6-month treatment
∗ www.maps.google.com
Treatment of LTBI
were compared to patients who did not complete treatment. Relative risks (RRs) were calculated with a
modified Poisson regression with a robust error variance.18 Odds ratios (ORs) were calculated with single
and multivariate logistic regression models. Adjustments were made for clustering by household.
RESULTS
Between 30 November 2006 and 15 February 2008,
301 HHCs of 76 patients hospitalized with pulmonary
TB agreed to participate in the study and were administered TST; 261 (86.7%) returned to HEOM to
have their TST result read. Of these 261, 145 (55.6%)
had a positive TST result, of whom 101 (69.7%) initiated LTBI treatment. The 101 HHCs represented 39
distinct households in Salvador, with a median of two
study participants per household. Of the 44 (30.3%)
HHCs who did not initiate LTBI treatment, 10 (23%)
did not meet the criteria for treatment and 34 (77%)
refused treatment; interview data were not available
for these 34 HHCs. Four HHCs reported diabetes.
None of the study participants were on antiretroviral
treatment, and none had been previously treated for
TB or LTBI.
Of the 101 HHCs who initiated LTBI treatment,
29 (28.7%) were immediately lost to follow-up (Table 1). At the end of the 6-month follow-up, 54
(53.5%) of 101 HHCs had completed treatment and
47 (46.5%) had not (Table 1).
Adverse effects
Nine (13%) of the 72 HHCs who returned for one or
more follow-up visits reported adverse effects; three
(4%) reported major gastrointestinal symptoms (nausea, vomiting and abdominal pain). Blood tests for
bilirubin, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase and akaline
phosphatase were performed on these patients; the
results were all within normal range. The remaining
six (8%) reported loss of appetite, acne and/or skin
rash; these effects disappeared over the course of the
treatment in all six. There were no cases of peripheral
neuropathy or hepatotoxicity.
Risk for failure to complete LTBI treatment
Of the nine HHCs who reported any adverse effects,
five (56%) did not complete treatment, while of 63
HHCs who did not report side effects, 13 (21%) did
not complete treatment (RR 2.69, 95% confidence
interval [CI] 1.3–5.8, P = 0.01; Table 2).
Of the 61 HHCs who took two buses to commute
to HEOM, 32 (52%) did not complete LTBI treatment, while of 35 HHCs who took one bus in a oneway commute, 10 (29%) did not complete treatment
(RR 1.84, 95%CI 1.0–3.3, P = 0.04; Table 2). After
adjusting for the distance between their residence and
HEOM, there was no association between the num-
721
Table 1 Characteristics of household contacts* who initiated
LTBI treatment, N = 101
Characteristics
Age, years
0–10
11–21
22–39
⩾40
Male sex
Ethnicity†
Black
Multiracial
White
Presence of BCG scar
Current employment status‡
Family income, US$§
210–420
630–840
Did not say
Distance from HEOM, km¶
⩽5
5.1–10
>10
Number of buses required to
commute to HEOM#
One
Two
Relationship to index case
Spouse/child/parent
Aunt /uncle/cousin/neighbor/
grandparent /sibling
Time of exposure to index case
⩾2.7 months
Number of 30-day INH refills received
1
2
3
4
5
6
n (%)
median 23
14
33
30
24
44 (44)
49 (52)
36 (38)
10 (10)
82 (81)
29 (48)
mean 525
35 (34.7)
39 (38.6)
27 (26.7)
28 (29)
29 (31)
38 (40)
35 (35)
61 (64)
42 (42)
59 (58)
mean 2.7 months
33 (33)
29 (29.7)
10 (9.9)
3 (3.0)
5 (5.0)
0
54 (53.5)
* Data were not available for the 34 HHCs who were eligible for the study
but who refused to participate.
† Six individuals did not report their ethnicity.
‡ Only the 61 HHCs aged ⩾18 years were asked for their employment status.
§ Family income was approximated and categorized, and includes only the
monthly income of household members aged ⩾18 years.
¶ Data not available for six individuals.
# The number of buses a study participant must take in a one-way commute
between their residence and the hospital; data not available for five individuals.
LTBI = latent tuberculosis infection; BCG = bacille Calmette-Guérin; HEOM =
Hospital Especializado Octávio Mangabeira; INH = isoniazid; HHC = household contact.
ber of buses a study participant took and failure to
complete LTBI treatment (adjusted RR 1.38, 95%CI
0.7–2.6, P = 0.31).
Of 38 HHCs who lived at a distance of >10 km
from HEOM, eight (21%) did not complete treatment, while of 28 HHCs who lived within 5 km of
HEOM, 15 (54%) did not complete treatment (RR
0.39, 95%CI 0.2–0.8, P = 0.01; Table 2). After adjusting for the number of buses a HHC took in a oneway commute between their home and HEOM,
HHCs who lived at a distance of >10 km had a lower
risk of treatment failure compared to those who lived
within 5 km of HEOM (adjusted RR 0.40, 95%CI
0.2–0.8, P = 0.01).
722
The International Journal of Tuberculosis and Lung Disease
Table 2 Risk for failure to complete 6 months of isoniazid treatment for latent tuberculosis
infection among HHCs of index cases hospitalized with pulmonary tuberculosis*
Age, years
0–10
11–21
22–39
⩾40
Male sex
Relationship to index case
Spouse, child, parent
Aunt, uncle/cousin/neighbor/
grandparent /sibling
Report of adverse effects§
Monthly family income, US$
210–420
630–840
Did not say
Distance to HEOM, km¶
0–5
5.1–10
>10
Number of buses required to
commute to HEOM#
One
Two
Treatment
non-completion
(n = 47)
n (%)
Treatment
complete
(n = 54)
n (%)
RR (95%CI)†
P value‡
median 23
7 (15)
15 (32)
13 (28)
12 (26)
19 (40)
median 24
7 (13)
18 (33)
17 (31)
12 (22)
25 (46)
0.0
0.91 (0.5–1.7)
0.87 (0.4–1.7)
1 (0.5–1.9)
0.88 (0.57–1.35)
0.77
0.67
1.0
0.56
22 (47)
20 (37)
1.24 (0.8–1.9)
0.32
25 (53)
5 (28)
34 (63)
4 (7)
0.0
2.69 (1.3–5.8)
0.01
12 (25)
21 (45)
14 (30)
23 (43)
18 (33)
13 (24)
0.64 (0.4–1.1)
0.0
—
0.11
15 (37)
18 (44)
8 (20)
13 (24)
11 (20)
30 (56)
0.0
1.16 (0.7–1.8)
0.39 (0.2–0.8)
—
0.52
0.01
10 (24)
32 (76)
25 (46)
29 (54)
0.0
1.84 (1.0–3.3)
0.04
—
* Generalized linear models were built in Stata.
† Based on robust standard errors that account for clustering by household.
‡ Fisher’s exact P values.
§ Data only available for patients who returned at least once for a follow-up visit; reports of adverse effects are available for 18 HHCs who did not complete treatment.
¶ Data not available for six individuals who did not complete INH.
# Data not available for five individuals who did not complete INH.
HHC = household contact; RR = relative risk; CI = confidence interval; HEOM = Hospital Especializado Octávio
Mangabeira.
Subgroup analysis of HHCs immediately lost to
follow-up
Of the 53 HHCs who took two buses to commute to
HEOM, 24 (45%) were immediately lost to followup, while of the 26 HHCs who took one bus, one
(4%) was immediately lost to follow-up (OR =
20.69, 95%CI 2.1–208.4, P = 0.01; Table 3).
DISCUSSION
A recent systematic review of INH trials of ⩾6 months
in non-HIV-infected persons from 1955 to 2003 found
that among 11 relevant studies selected for review,
only two were conducted among HHCs of index TB
cases in TB-endemic countries—Kenya (1963) and
the Philippines (1965).19 All others were conducted in
the United States and other industrialized countries,
or in cohorts with underlying medical problems.19
Today, neither Kenya nor the Philippines routinely
conduct contact investigations to identify candidates
for INH treatment. Our study, in a country that administers BCG to prevent TB, found that INH treatment, when offered, was well accepted (77%) and tolerated. Furthermore, we found that of the 101 HHCs
who initiated LTBI treatment, slightly more than
50% completed the full 6-month course. This completion rate falls towards the higher end of completion rates reported in the United States for 6 months
of LTBI treatment.6,20 Our rate of treatment completion may be attributed to prospective study enrollment.20 However, a prospective study that enrolled
pediatric HHCs of pulmonary TB patients in Cape
Town, South Africa, found that only 36/180 (20%)
completed <5 months of INH treatment.21
There are no reported studies on factors associated with failure to complete INH treatment for LTBI
in non-HIV-infected persons in countries that administer BCG to prevent TB. Two recent articles that examined time to treatment failure are from studies
conducted in the United States.22,23 A retrospective
cohort study of LTBI patients at the Boston Medical
Center TB clinic in 1998 found that over half of the
patients who initiated LTBI treatment and did not
complete it were lost to follow-up within the first
month.22 This study did not investigate risk factors
for immediate loss to follow-up.
Of the 47 HHCs who did not complete 6 months
of treatment, 42 (89%) did not return for INH refills
after the third month of treatment, and nearly two
thirds of non-completers were immediately lost to
Treatment of LTBI
723
Table 3 Risk factors for immediate loss to follow-up among HHCs of index cases hospitalized
with pulmonary tuberculosis who initiated treatment for latent tuberculosis infection*
Age, years
0–10
11–21
22–39
⩾40
Male sex
Relationship to index case
Spouse, child, parent
Aunt, uncle/cousin/ neighbor/
grandparent /sibling
Monthly family income, US$
210–420
630–840
Did not say
Report of adverse effects§
Distance to HEOM, km¶
0–5
5.1–10
>10
Number of buses required to
commute to HEOM#
One
Two
Treatment
stopped in
first month
(n = 29)
n (%)
Treatment
complete
(n = 54)
n (%)
OR (95%CI)†
P value‡
median: 23
6 (21)
8 (28)
6 (21)
9 (31)
11 (38)
median: 24
7 (13)
18 (33)
17 (31)
12 (22)
25 (46)
1.0
0.52 (0.1–2.0)
0.23 (0.1–1.7)
0.85 (0.2–3.5)
0.71 (0.3–1.8)
0.35
0.23
0.88
0.46
13 (45)
20 (37)
1.38 (0.4–5.0)
0.49
16 (55)
34 (63)
1.0
5 (17)
19 (66)
5 (17)
n/a
23 (43)
18 (33)
13 (24)
4 (7)
0.21 (0.02–1.9)
1.0
—
—
8 (32)
13 (52)
4 (16)
13 (24)
11 (20)
30 (56)
1.0
1.92 (0.2–22.2)
0.22 (0.2–3.0)
0.60
0.25
1 (4)
24 (96)
25 (46)
29 (54)
1.0
20.69 (2.1–208.4)
0.01
0.17
—
—
*Logistic regression models were built in Stata.
†Standard errors are adjusted to account for clustering by household for household level variables (monthly family
income, distance to HEOM, time of exposure to index case, number of buses required to reach HEOM).
‡Fisher’s exact P values.
§Data not available for study participants who did not return for any follow-up visits.
¶ Data not available for six individuals, four of whom stopped treatment in the first month.
# Data not available for five individuals, four of whom stopped treatment in the first month.
HHC = household contact; OR = odds ratio; CI = confidence interval; HEOM = Hospital Especializado Octávio
Mangabeira.
follow-up (Table 1). HHCs requiring a 2-bus commute to the hospital accounted for 96% of those immediately lost to follow-up (Table 3). The number of
buses a study participant is required to take in a oneway commute between their residence and HEOM is
not related to the distance the HHC lives from the
hospital. Our findings suggest that the number of bus
trips, and not distance, is the variable that best describes HHCs who did not complete treatment.
A significant proportion of the 47 HHCs who
completed treatment lived at a distance of >10 km
from HEOM (Table 2). There is no plausible explanation as to why living farther from the hospital
would promote treatment completion; this is likely to
be a spurious finding. When we adjusted for the distance between residence and HEOM, a 2-bus commute was not independently predictive of failure to
complete INH treatment (Table 2). We believe that
the true association between the number of bus trips
and failure to complete INH treatment was blurred
by the spurious association between the farthest distance category and treatment completion. Most of
these 47 were immediately lost to follow-up. The
sub-group analysis that excludes the eight HHCs
who did not complete treatment but who were not
immediately lost to follow-up eliminates the association between distance and completion of LTBI treatment (Table 3).
At the time of our study, the bus fare in Salvador
was about US$1, and users must pay the full fare
again when transferring to another bus. The median
number of study participants per household was two;
these households paid US$8 per month in bus fares
to participate in the study if they had a two-bus roundtrip commute. This is a considerable cost, given the
mean monthly family income in our study population of US$525 (Table 1). Income itself was not associated with treatment completion because there was
little variation in income distribution in our study
population (income range US$210–$840; Table 1).
Our findings suggest that subsidizing bus rides for
patients would greatly improve the number of INH
refills a patient receives and, ultimately, LTBI treatment completion.
This observation in Brazil suggests that a routine
LTBI treatment program could be introduced in a
high-risk population if it is coordinated by a team
that reliably supplies INH and monitors for adverse
724
The International Journal of Tuberculosis and Lung Disease
effects. We also found that if the patients returned for
the first follow-up visit, LTBI treatment, with close
monitoring and reassurance, was well accepted and
tolerated. Most importantly, we identified factors that
contribute to non-completion of the 6-month treatment course in an endemic setting. Treatment tolerability and the ease of monthly commute between the
patient’s residence and the hospitals using public
transport are good predictors of whether an individual will complete treatment. In summary, an LTBI
treatment program focused on HHCs in a country
that administers BCG is feasible and should be considered as a major part of an NTP.
Acknowledgements
The authors thank the director of the HOEM and the clinical laboratory at the hospital. Financial support was provided by NIH
Fogarty International Center 5U2RTW 006885.
References
1 Morrison J, Pai M, Hopewell P C. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary
tuberculosis in low-income and middle-income countries: a
systematic review and meta-analysis. Lancet Infect Dis 2008;
8: 359–368.
2 Lemos A C, Matos E D, Pedral-Sampaio D B, Netto E M. Risk
of tuberculosis among household contacts in Salvador, Bahia.
Braz J Infect Dis 2004; 8: 424–430.
3 Caldeira Z M, Sant’Anna C C, Aide M A. Tuberculosis contact
tracing among children and adolescents, Brazil. Rev Saude
Publica 2004; 38: 339–345.
4 Parrish N M, Dick J D, Bishai W R. Mechanisms of latency in
Mycobacterium tuberculosis. Trends Microbiol 1998; 6: 107–
112.
5 Radhakrishna S, Frieden T R, Subramani R, Santha T, Narayanan P R. Additional risk of developing TB for household members with a TB case at home at intake: a 15-year study. Int J
Tuberc Lung Dis 2007; 11: 282–288.
6 American Thoracic Society. Targeted tuberculin testing and
treatment of latent tuberculosis infection. MMWR 2000; 49:
1–51.
7 Broekmans J F, Migliori G B, Rieder H L, et al. European
framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World
Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands
Tuberculosis Association (KNCV) Working Group. Eur Respir
J 2002; 19: 765–775.
8 Jasmer R M, Nahid P, Hopewell P C. Clinical practice. Latent
tuberculosis infection. N Engl J Med 2002; 347: 1860–1866.
9 Saukkonen J J, Cohn D L, Jasmer R M, et al. An official ATS
statement: hepatotoxicity of anti-tuberculosis therapy. Am J
Respir Crit Care Med 2006; 174: 935–952.
10 World Health Organization. Treatment of tuberculosis: guidelines for national programmes. Geneva, Switzerland: WHO,
2003.
11 World Health Organization. Guidelines for national tuberculosis programmes on the management of tuberculosis in children.
Geneva, Switzerland: WHO, 2006.
12 Castelo-Filho A, Kritsky A L, Barreto A W, et al. Sociedade
Brasileira de Pneumologia e Tisiologia. II Consenso Brasileiro
de Tuberculose. Diretrizes Brasileiras para Tuberculose 2004.
J Bras Pneumol 2004; 30 (Suppl): S2–S56. [Portuguese]
13 Ministerio do Planejamento Orçamento e Gestão. Instituto Brasileiro de Geografia e Estatistica. 2008. http://www1.ibge.gov.br/
home/estatistica/populacao Accessed May 2008. [Portuguese]
14 Ministério da Saúde Secretaria de Políticas de Saúde Brazil.
DATASUS. 2008. http://tabnet.datasus.gov.br Accessed December 2008. [Portuguese]
15 International Union Against Tuberculosis and Lung Disease.
Sputum examination for tuberculosis by direct microscopy in
low-income countries. Technical guide. Paris, France: The
Union, 2000. http://www.iuatld.org/pdf/en/guides_publications/
microscopy_guide.pdf Accessed April 2008.
16 Machado A, Emodi K, Takenami I, et al. Analysis of discordance between tuberculin skin test and interferon-gamma release assay. Int J Tuberc Lung Dis 2009; 13: 446–453.
17 Behr M A, Hopewell P C, Paz E A, Kawamura L M, Schecter G
F, Small P M. Predictive value of contact investigation for identifying recent transmission of Mycobacterium tuberculosis. Am
J Respir Crit Care Med 1998; 158: 465–469.
18 Zou G. A modified poisson regression approach to prospective
studies with binary data. Am J Epidemiol 2004; 159: 702–706.
19 Smieja M J, Marchetti C A, Cook D J, Smaill F M. Isoniazid for
preventing tuberculosis in non-HIV infected persons. Cochrane
Database Syst Rev 2000 (2): CD001363.
20 Page K R, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment
of latent tuberculosis: a retrospective study. Arch Intern Med
2006; 166: 1863–1870.
21 Marais B J, van Zyl S, Schaaf H S, van Aardt M, Gie R P,
Beyers N. Adherence to isoniazid preventive chemotherapy: a
prospective community based study. Arch Dis Child 2006; 91:
762–765.
22 Parsyan A E, Saukkonen J, Barry M A, Sharnprapai S, Horsburgh C R Jr. Predictors of failure to complete treatment for
latent tuberculosis infection. J Infect 2007; 54: 262–266.
23 Kwara A, Herold J S, Machan J T, Carter E J. Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island. Chest 2008; 133: 862–
868.
RÉSUMÉ
Bien que le traitement de l’infection tuberculeuse latente (LTBI) soit une composante essentielle de
la lutte antituberculeuse dans des pays comme les EtatsUnis, on n’y recourt pas fréquemment dans la plupart
des pays où l’endémie tuberculeuse est importante.
O B J E C T I F : Examiner la pratique et l’adhésion au traitement de la LTBI dans une population à haut risque au
Brésil.
S C H É M A : Nous avons suivi à Salvador, Brésil, pendant
6 mois après le début du traitement de la LTBI par l’isoCADRE :
niazide (INH), les contacts au sein du ménage (HHC) de
patients hospitalisés pour une tuberculose (TB) pulmonaire. On a demandé aux HHC de revenir à l’hôpital
une fois par mois pendant 6 mois pour les visites de
suivi et pour obtenir leur réapprovisionnement d’INH.
R É S U LTAT S : Le régime de 6 mois a été achevé chez 54
(53,5%) des 101 HHC qui ont commencé le traitement
de la LTBI. Le risque de non-achèvement du traitement
est significativement plus élevé chez les HHC qui ont
signalé des effets indésirables de l’INH (RR 2,69 ;
Treatment of LTBI
IC95% 1,3–5,8 ; P = 0,01), ainsi que chez les HHC qui
devaient prendre deux bus pour un voyage aller vers
l’hôpital (RR 1,8 ; IC95% 1,01–3,3 ; P = 0,04). Sur
les 101 HHC qui ont commencé le traitement de la
LTBI, 29 (28,7%) ne sont revenus pour aucune visite
de suivi ; ces HHC avaient des chances significativement plus élevées d’avoir à changer deux fois de bus
pour aller à l’hôpital par comparaison avec ceux qui ont
725
achevé leur traitement (OR 20,69 ; IC95% 2,1–208,4 ;
P = 0,01).
C O N C L U S I O N : Près de la moitié des HHC à haut risque
de développement d’une TB ont achevé un traitement de
6 mois pour la LTBI. L’achèvement du traitement de la
LTBI est le plus affecté par l’intolérance à l’égard des
médicaments et les difficultés de correspondance des
transports publics pour les visites de suivi.
RESUMEN
Si bien el tratamiento de la
infección tuberculosa latente (LTBI) en países como los
Estados Unidos constituye un componente esencial de la
lucha contra la enfermedad, esta práctica no está muy
difundida en la mayoría de los países endémicos.
O B J E T I V O : Se evaluar la aplicación y el cumplimiento
terapéutico del tratamiento de la LTBI en una población
de alto riesgo del Brasil.
M É T O D O : Se practicó un seguimiento a los contactos
domiciliarios (HHC) de pacientes hospitalizados por tuberculosis (TB) pulmonar durante 6 meses, desde que comenzaron el tratamiento preventivo con isoniazida (INH),
en Salvador, Brasil. Se solicitó a los HHC que acudieran
al hospital una vez por mes durante el seguimiento para
control y suministro de las dosis del medicamento.
R E S U LTA D O S : De los 101 HHC que iniciaron el tratamiento, 54 (53,5%) completaron la pauta de 6 meses. El
riesgo de tratamiento incompleto fue significativamente
MARCA DE REFERENCIA :
más alto en los HHC que refirieron reacciones adversas a la INH (RR 2,69 ; IC95% 1,3–5,8 ; P = 0,01) y
en quienes debían tomar dos buses en cada desplazamiento hacia el hospital (RR 1,8 ; IC95% 1,01–3,3 ;
P = 0,04). De los 101 HHC que comenzaron el tratamiento preventivo, 29 (28,7%) no acudieron a ninguna
cita de control ; en estos contactos, la probabilidad de
tener un trayecto con dos buses para llegar al hospital
fue significativamente más alta que en los contactos que
completaron el tratamiento (OR 20,69 ; IC95% 2,1–
208,4 ; P = 0,01).
C O N C L U S I Ó N : Cerca de la mitad de los HHC con alto
riesgo de padecer TB activa completaron el tratamiento
preventivo de 6 meses. Los principales factores que influyeron sobre la compleción del tratamiento de la LTBI
fueron la intolerabilidad al medicamento y las dificultades con el transporte público para asistir a las consultas
de control.